



13th ANRS HBV Cure Workshop Program
25th & 26th March 2026, at Institut Lumière, Lyon, France

Wednesday, 25th March 2026

Joint opening and closing statements for RNH / HBV Cure Workshop 10:30 – 10:45

Yazdan Yazdanpanah, Éloi Verrier & Fabien Zoulim

Young investigator session 10:45 – 12:15

Chairs: Jean-Michel Pawlotsky and Éloi Verrier

HBV cure and RNH joint session

Keynote lecture: (20' + 10 questions) 12:15 – 12:45

What are the knowledge gaps to cure HBV and HDV infections?

Massimo Levrero, Lyon

Lunch break (1:05')

Best Young Researcher Presentation Award 13:50

Viral genome persistence 14:00 – 14:50

Chairs: Christine Neuveut and Guillaume Giraud

Viral chromatin: the role of nucleosome occupancy in cccDNA transcription

Robert Schwartz, New York (20' + 5')

Episomal and integrated hepatitis B transcriptome mapping in the liver of CHB patients

Jane McKeating, Oxford (20' + 5')

Immunological determinants of viral persistence 14:50 – 15:40

Chairs: Pierre Tonnerre and Hélène Strick-Marchand

HBV specific T cell modulation

Maike Hofmann, Freiburg (20' + 5')

HBV specific B cell responses

Lucy Cooper, London (20' + 5')

Break (20')

The liver reservoir of infection 16:00 – 17:15

Chairs: Andres Roca and David Durantel

Spatial single-cell omics: new insights into liver diseases.

Bertram Bengsch, Freiburg (20' + 5')

Single-cell landscape of the myeloid cell adaptations during liver fibrosis

Moritz Peiseler, Berlin (20' + 5')

Heterogeneity of HBV/HDV and immune response distribution in the liver

Maëlle Locatelli (20' + 5')

End of day 17:30



13th ANRS HBV Cure Workshop Program
25th & 26th March 2026, at Institut Lumière, Lyon, France

Thursday 26th March, 2026

Novel therapies – Translational studies 8:30 – 10:10

Chairs: Patrick Soussan and Barbara Testoni

Induction of HBV-specific immune responses in immunocompetent humanized mice

Hélène Strick-Marchand, Paris **(20' + 5')**

Development of novel therapeutic vaccine candidates

Anna Kosinska, Munich **(20' + 5')**

Gene and epigenome editing of HBV

Anuj Kumar & Fabien Zoulim, Lyon **(20' + 5')**

New approach to target HDV with antisense oligonucleotides

Julie Lucifora, Lyon **(20' + 5')**

Break (15')

Cohort studies 10:25 – 11:40

Chairs: Vincent Thibault and Lucia Parlati

Hepatocellular carcinoma risk in a real-life cohort of chronic hepatitis B

Marc Bourlière, Marseille **(20' + 5')**

Immune profiling of patients with CHB and CHD

Upkar Gill, London **(20' + 5')**

Artificial intelligence in cohort studies and clinical trials for CHB and CHD

Anders Boyd, Bern **(20' + 5')**

Novel therapies – Progress in clinical development 11:40 – 12:55

Chairs: Vincent Leroy and Hélène Fontaine

Treatment endpoints to guide clinical development of novel therapies

Jordan Feld, Toronto **(20' + 5')**

Advances in RNA interference development

Man-Fung Yuen, Hong Kong **(20' + 5')**

An update on Bulevirtide and novel treatments for CHD

Elisabetta Degespari, Milan **(20' + 5')**

Farewell and buffet lunch